文献速递神经核医学肿瘤 PET/CT

口服蛋白质摄入对胶质瘤[18F]FET-PET摄取及重测重复性的前瞻性临床研究

A prospective clinical study of the influence of oral protein intake on [18F]FET-PET uptake and test-retest repeatability in glioma.
PubMed 文献 · EJNMMI Res · 2024-06-26

该前瞻性临床研究评估了胶质瘤患者[18F]FET-PET摄取指标的重测重复性,并分析检查前口服蛋白质摄入的影响。无蛋白摄入组TBRmean、TBRmax和BTV的重测变异度较好,摄取比值优于BTV。检查前1小时口服24g蛋白质使血浆LAT1相关氨基酸总量升高27%,肿瘤和正常脑组织SUV下降,但对常用肿瘤指标TBRmean和TBRmax的影响仅边缘显著。

要点

  • 无蛋白摄入组TBRmean和TBRmax的重测重复性优于BTV。
  • 检查前1小时口服24g蛋白质使血浆LAT1相关氨基酸总量升高27%。
  • 蛋白质摄入使肿瘤最大SUV降低14%、正常脑组织平均SUV降低25%。

核心结论

  • 重测重复性良好,TBRmax和TBRmean优于BTV,方法学局限是肿瘤生长可能影响结果。
  • 检查前1小时口服24g蛋白质降低肿瘤和正常脑组织[18F]FET摄取,但对最常用肿瘤指标无临床显著差异。

研究设计与样本

  • 前瞻性临床研究,评估胶质瘤患者[18F]FET-PET摄取指标的重测重复性及检查前口服蛋白质摄入的影响。
  • 原文未报告样本量、分组例数及研究时间范围。

主要发现

  • 无蛋白摄入组TBRmean的绝对(相对)上下限一致性界限为+0.15和-0.13(+9.7%和-9.0%)。
  • 无蛋白摄入组TBRmax的绝对(相对)上下限一致性界限为+0.43和-0.28(+19.6%和-11.8%)。
  • 无蛋白摄入组BTV的绝对(相对)上下限一致性界限为+2.14 cm³和-1.53 ml(+219.8%和-57.3%)。
  • 蛋白质摄入使血浆LAT1相关氨基酸总量升高27%,使正常脑组织平均SUV降低25%、肿瘤最大SUV降低14%。
  • 检查前1小时口服24g蛋白质有增加变异性的趋势,但对TBRmean和TBRmax的影响仅边缘显著,变化通常在无蛋白摄入组观察到的变异范围内。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 方法学局限是肿瘤生长可能影响结果。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: O-(2-[18F]fluoroethyl)-L-tyrosine positron emission tomography ([18F]FET PET) scanning is used in routine clinical management and evaluation of gliomas with a recommended 4 h prior fasting. Knowledge of test-retest variation of [18F]FET PET imaging uptake metrics and the impact of accidental protein intake can be critical for interpretation. The aim of this study was to investigate the repeatability of [18F]FET-PET metrics and to assess the impact of protein-intake prior to [18F]FET PET scanning of gliomas. RESULTS: Test-retest variability in the non-protein group was good with absolute (and relative) upper and lower limits of agreement of + 0.15 and - 0.13 (+ 9.7% and - 9.0%) for mean tumour-to-background ratio (TBRmean), + 0.43 and - 0.28 (+ 19.6% and - 11.8%) for maximal tumour-to-background ratio (TBRmax), and + 2.14 cm3 and - 1.53 ml (+ 219.8% and - 57.3%) for biological tumour volume (BTV). Variation was lower for uptake ratios than for BTV. Protein intake was associated with a 27% increase in the total sum of plasma concentration of the L-type amino acid transporter 1 (LAT1) relevant amino acids and with decreased standardized uptake value (SUV) in both healthy appearing background brain tissue (mean SUV - 25%) and in tumour (maximal SUV - 14%). Oral intake of 24 g of protein 1 h prior to injection of tracer tended to increase variability, but the effects on derived tumour metrics TBRmean and TBRmax were only borderline significant, and changes generally within the variability observed in the group with no protein intake. CONCLUSION: The test-retest repeatability was found to be good, and better for TBRmax and TBRmean than BTV, with the methodological limitation that tumour growth may have influenced results. Oral intake of 24 g of protein one hour before a [18F]FET PET scan decreases uptake of [18F]FET in both tumour and in healthy appearing brain, with no clinically significant difference on the most commonly used tumour metrics.

来源:EJNMMI Res,查看原文。版权归原作者所有。

引用

  1. Chehri S, Henriksen OM, Marner L, et al. A prospective clinical study of the influence of oral protein intake on [18F]FET-PET uptake and test-retest repeatability in glioma. EJNMMI Res. 2024. PMID: 38922458. doi:10.1186/s13550-024-01119-0

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。